Vorapaxar in the Secondary Prevention of Atherothrombotic Events

Study Questions:

What is the role of vorapaxar, a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of protease-activated receptor (PAR-1), for secondary prevention of atherothrombotic events?